Form 4: SpringWorks Therapeutics Director Hambleton Receives Stock and Option Grants

Julie Hambleton, a director at SpringWorks Therapeutics, received stock and option grants as part of the company's non-employee director compensation policy.

Summary

• On May 16, 2024, Julie Hambleton, a director at SpringWorks Therapeutics, received 4,095 shares of common stock and an option to buy 12,216 shares of common stock.
• These grants were made under the company's Amended and Restated Non-Employee Director Compensation Policy.
• The stock was granted at a price of $0.
• The options have an exercise price of $44.77.
• Both the stock and options vest fully on the earlier of May 16, 2025, or the date of the next annual meeting of stockholders, contingent upon continued service to the Issuer by the Reporting Person.
• Following the transaction, Hambleton beneficially owns 8,743 shares of common stock and options for 12,216 shares.

Sentiment

Score: 7

Explanation: The document reflects standard director compensation practices, indicating stability and alignment of interests. It's a neutral to slightly positive signal.

Positives

• The equity grants align the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service to the company.

Future Outlook

The grants are part of an ongoing compensation policy for non-employee directors, suggesting continued equity-based compensation in the future.

Industry Context

Equity grants to directors are a common practice in the pharmaceutical industry to align their interests with those of shareholders and incentivize long-term value creation.

Stakeholder Impact

• The equity grants align the director's interests with those of the shareholders, potentially leading to better decision-making.
• The grants do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates